SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GUMM - Eliminate the Common Cold

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: StockDung6/24/2009 12:33:46 PM
   of 5582
 
MATRIXX UPGRADED TO INVESTIGATION BY THE SEC.

==========================================================

Matrixx recalls Zicam nasal cold products
Matrixx Initiatives recalls Zicam nasal cold remedies in wake of FDA safety warning

On Wednesday June 24, 2009, 11:16 am EDT
finance.yahoo.com

Matrixx initiatives inc.
NEW YORK (AP) -- Matrixx Initiatives Inc. said Wednesday it started a previously announced recall of Zicam nasal cold remedies following last week's Food and Drug Administration warning that the products were unsafe.

Meanwhile, the company is being investigated by the Securities and Exchange Commission over the FDA warning letter.
The Scottsdale, Ariz., company said the recall was voluntary. Still, it occurred as the FDA warned consumers to not use the nasal cold remedies due to hundreds of reports of patients losing their sense of smell. Matrixx said it disagrees with the FDA's safety warning, but "voluntarily" recalled the product to cooperate with the regulatory agency.

The FDA also alleges the products were unlawfully marketed. Matrixx also disagrees with that allegation.

"The company is also in the process of preparing a submission to the FDA and, as previously reported, will soon ask to meet with the agency to present comprehensive scientific and medical data and analyses demonstrating that these products are safe," Matrixx said, in a statement.

On June 16, the FDA issued the recall notice for Zicam products, which accounted for 40 percent of Matrixx's sales last year. The regulatory agency said the products contain zinc, which could damage nerves in the nose needed for smell.

Matrixx has settled hundreds of lawsuits connected with Zicam in recent years, though it maintains the nasal spray does not harm users' sense of smell.

Shares of Matrixx rose 3 cents to $4.86 in morning trading. The stock has lost three-quarters of its value since the FDA issued its warning last week.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext